Adamas soars as its Parkinson’s drug comes through in Phase III

Damian Garde

Pharmaceuticals' lead met its main goals of reducing side effects related to Parkinson's disease treatment in a late-stage trial, the company said, clearing the way for an FDA submission.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS